Official Human Gene Symbol
AHCY is the approved symbol used by NCBI, HGNC, ClinVar, genetic laboratories, and clinical databases.
Learn how the AHCY gene produces S-adenosylhomocysteine hydrolase, commonly called SAHH, and why clearing S-adenosylhomocysteine is important for continued methyl-transfer reactions.
A genetic methylation report may include a variant in AHCY. The meaning depends on the exact variant, genotype, evidence, and testing purpose—not simply the gene name, a red report label, or the presence of one altered allele.
AHCY provides instructions for the SAHH enzyme, which catalyzes the reversible breakdown of S-adenosylhomocysteine into adenosine and homocysteine.
SAH is created after S-adenosylmethionine, or SAM, donates a methyl group. Because SAH can inhibit many SAM-dependent methyltransferases, processing it is important for maintaining the flow of methylation reactions. This does not mean that an AHCY genotype directly measures a person’s current methylation capacity.
Reports and educational articles may use several names for the same gene and protein. Knowing the distinction makes database searches and result interpretation more accurate.
AHCY is the approved symbol used by NCBI, HGNC, ClinVar, genetic laboratories, and clinical databases.
SAHH is short for S-adenosylhomocysteine hydrolase. It is also listed as an alias for AHCY.
Some scientific records use adenosylhomocysteinase or AdoHcyase. These terms should not be confused with AHCYL1 or AHCYL2.
AHCY is sometimes described as a methylation “gatekeeper” because it processes a by-product that can oppose methyltransferase activity.
Review SNPs and methylation and genetic variants versus mutations before interpreting one highlighted AHCY result.
AHCY functions after SAM has donated a methyl group and before homocysteine continues into remethylation or transsulfuration.
Methionine enters the cycle from dietary protein and the recycling of homocysteine.
Methionine adenosyltransferase enzymes convert methionine and ATP into SAM.
SAM donates a methyl group through a methyltransferase reaction and becomes SAH.
SAHH processes SAH into adenosine and homocysteine through a reversible reaction.
Homocysteine can return toward methionine or enter the transsulfuration pathway.
These concepts explain the biological relevance of AHCY without turning one consumer genetic result into a medical conclusion.
SAH is created as a normal result of SAM-dependent methyltransferase reactions.
Higher intracellular SAH can oppose methyltransferase activity, making its removal relevant to pathway flow.
The AHCY reaction links methyl transfer with adenosine, homocysteine, remethylation, and transsulfuration pathways.
The report identifies inherited DNA at a tested location. It does not directly measure the current biochemical pathway.
Different AHCY variants can have very different classifications. Interpret the exact DNA change rather than a general “SAHH” label.
Search clinical databases using AHCY rather than relying only on the SAHH alias.
Record the rsID or HGVS notation, including the transcript version when it is available.
Confirm the alleles and zygosity. Clinical AHCY deficiency is generally associated with disease-causing variants in both copies.
Review classification, submitter, review status, functional evidence, population frequency, and evaluation date.
A wellness-panel label is not a clinical diagnosis. Terms such as “slow,” “reduced,” “risk,” or “impaired” may be proprietary interpretations. Check whether the exact AHCY variant has an established clinical classification before drawing a conclusion.
Rare inherited SAHH deficiency involves a different level of evidence, testing, and medical follow-up from a common consumer-report variant.
This may be a common SNP included for educational pathway context. Its presence does not establish reduced enzyme activity or disease.
This rare metabolic condition requires clinical assessment, biochemical testing, and appropriate diagnostic genetic testing.
AHCY processes SAH, but other genes help produce SAM, remethylate homocysteine, and direct sulfur compounds through connected pathways.
Depending on the panel, related genes may include genes involved in methionine activation, folate-dependent remethylation, vitamin B12–dependent reactions, choline-related remethylation, and transsulfuration.
Broader coverage is most useful when the report identifies the exact variants, explains the strength of the evidence, and clearly states what the findings do not measure.
A consumer genetic report can be collected at home, but follow-up depends on the type of finding and the healthcare services available in your area.
For report-format questions, begin with the testing provider. A primary care clinician can assess symptoms and order conventional testing when appropriate. A genetic counselor can help review inheritance, family implications, and the quality of the variant evidence.
A rare pathogenic or likely pathogenic AHCY result, persistent hypermethioninemia, unusual muscle findings, developmental concerns, or an abnormal metabolic profile may require referral to a medical geneticist or biochemical genetics clinic. These services are often based at academic medical centers or children’s hospitals.
Smaller communities may not have a nearby metabolic genetics clinic. Ask whether a regional center offers an initial telehealth visit and confirm that the provider is licensed to see patients in your state.
Bring the entire report. A screenshot showing “SAHH slow” or a colored result is not enough to evaluate the variant, laboratory method, panel limitations, or clinical classification.
Reliable interpretation should use the official gene symbol, exact variant, current clinical classification, review status, population frequency, functional evidence, inheritance pattern, and biochemical context.
Direct answers about the official gene name, SAH processing, methylation, homocysteine, rare AHCY deficiency, and responsible result interpretation.
No. The official human gene symbol is AHCY. SAHH is a common abbreviation for S-adenosylhomocysteine hydrolase and is also listed as an AHCY alias.
AHCY provides instructions for the enzyme that catalyzes the reversible breakdown of S-adenosylhomocysteine into adenosine and homocysteine.
SAH is produced after SAM donates a methyl group. SAH can inhibit SAM-dependent methyltransferases, so its processing is relevant to the continued flow of methyl-transfer reactions.
No. A genetic report identifies inherited DNA at selected locations. It does not directly measure current SAH, SAM, adenosine, methionine, homocysteine, or enzyme activity.
No. A variant must be interpreted using its exact identity, genotype, classification, evidence, inheritance pattern, and clinical context. One variant does not measure whole-body methylation.
The rare clinical disorder caused by pathogenic AHCY variants is generally inherited in an autosomal-recessive pattern, meaning disease usually involves clinically significant variants in both gene copies.
Not by itself. The exact variant and its classification matter, and a single heterozygous result is not automatically diagnostic of an autosomal-recessive condition.
Rare pathogenic AHCY variants can cause a metabolic condition associated with hypermethioninemia and abnormal methionine-cycle metabolites. Diagnosis requires appropriate biochemical and clinical genetic testing.
Do not change supplements based only on a consumer genetic result. Decisions should consider the exact variant, current health, diet, medications, laboratory findings, and professional guidance.
A genetic counselor can review variant evidence and inheritance. A medical geneticist or biochemical genetics specialist may be appropriate when a rare pathogenic result or abnormal metabolic findings are present.
Confirm the official gene symbol, exact variant, genotype, clinical classification, evidence, panel coverage, and report limitations before deciding whether the finding is relevant.
Educational genetic information should support better questions—not replace biochemical testing, clinical genetics, or individual medical care.